(Q35622067)

English

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer

scientific article published on April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Electron Kebebew

15

object named as

Electron Kebebew

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

author name string

Lisa Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Yaqin Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Amit Mehta

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Myriem Boufraqech

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sean Davis

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jing Wang

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Ze Tian

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Zhiya Yu

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Matthew B Boxer

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Jeffrey A Kiefer

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

John A Copland

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Robert C Smallridge

12

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Zhuyin Li

13

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Min Shen

14

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

language of work or name

0 references

publication date

1 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

9073-9085

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

A new aurora in anaplastic thyroid cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

New and emerging HDAC inhibitors for cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

An in vivo mouse model of metastatic human thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Immunohistochemical detection of epithelialmesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Mutation of the PIK3CA gene in anaplastic thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

12 July 2018

Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

BRAF V600E inhibition in anaplastic thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

A phase II study of imatinib in patients with advanced anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

25 September 2018

The Role of Survivin in Thyroid Tumors: Differences of Expression in Well-Differentiated, Non–Well-Differentiated, and Anaplastic Thyroid Cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

15 November 2018

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496203

15 November 2018

Increasing incidence of thyroid cancer in the United States, 1973-2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Integrins in thyroid tissue: upregulation of alpha2beta1 in anaplastic thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone Deacetylase Inhibition Modulates E-Cadherin Expression and Suppresses Migration and Invasion of Anaplastic Thyroid Cancer Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anaplastic thyroid cancer: rare, fatal, and neglected

1 reference

https://pubmed.ncbi.nlm.nih.gov/25940539

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.18632/ONCOTARGET.3268

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35622067&oldid=1581949893"